The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Braude AC, Downar E, Chamberlain DW, Rebuck AS

Tocainide-associated interstitial pneumonitis.

Thorax. 1982;37(4):309-10

Perlow GM, Jain BP, Pauker SG, Zarren HS, Wistran DC, Epstein RL

Tocainide-associated interstitial pneumonitis.

Annals of internal medicine. 1981;94(4 pt 1):489-90

Van Natta B, Lazarus M, Li C

Irreversible interstitial pneumonitis associated with tocainide therapy.

The Western journal of medicine. 1988;149(1):91-2

Stein MG, Demarco T, Gamsu G, Finkbeiner W, Golden JA

Computed tomography: pathologic correlation in lung disease due to tocainide.

The American review of respiratory disease. 1988;137(2):458-60

Ahmad S

Tocainide: interstitial pneumonitis.

Journal of the American College of Cardiology. 1990;15(6):1458